IL214427A - Indole history as anticancer agents - Google Patents

Indole history as anticancer agents

Info

Publication number
IL214427A
IL214427A IL214427A IL21442711A IL214427A IL 214427 A IL214427 A IL 214427A IL 214427 A IL214427 A IL 214427A IL 21442711 A IL21442711 A IL 21442711A IL 214427 A IL214427 A IL 214427A
Authority
IL
Israel
Prior art keywords
anticancer agents
indole derivatives
indole
derivatives
anticancer
Prior art date
Application number
IL214427A
Other languages
English (en)
Hebrew (he)
Other versions
IL214427A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL214427A0 publication Critical patent/IL214427A0/en
Publication of IL214427A publication Critical patent/IL214427A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL214427A 2009-02-04 2011-08-03 Indole history as anticancer agents IL214427A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09152089 2009-02-04
PCT/EP2010/051316 WO2010089327A2 (en) 2009-02-04 2010-02-03 Indole derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
IL214427A0 IL214427A0 (en) 2011-09-27
IL214427A true IL214427A (en) 2016-02-29

Family

ID=40738626

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214427A IL214427A (en) 2009-02-04 2011-08-03 Indole history as anticancer agents

Country Status (23)

Country Link
US (1) US8541442B2 (de)
EP (1) EP2393801B1 (de)
JP (1) JP5612611B2 (de)
KR (1) KR101730407B1 (de)
CN (1) CN102307868B (de)
AR (1) AR075235A1 (de)
AU (1) AU2010210178B2 (de)
BR (1) BRPI1008855B8 (de)
CA (1) CA2749209C (de)
CL (1) CL2011001860A1 (de)
CO (1) CO6341625A2 (de)
EA (1) EA021883B1 (de)
ES (1) ES2639752T3 (de)
IL (1) IL214427A (de)
MX (1) MX2011008195A (de)
MY (1) MY152018A (de)
NO (1) NO20111199A1 (de)
NZ (1) NZ594186A (de)
SG (1) SG173495A1 (de)
TW (1) TWI476189B (de)
UA (1) UA107455C2 (de)
WO (1) WO2010089327A2 (de)
ZA (1) ZA201105695B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2841517B2 (ja) 1989-08-11 1998-12-24 株式会社ツムラ 入浴剤
JP2872763B2 (ja) 1990-06-28 1999-03-24 紀伊産業株式会社 携帯用肛門洗浄器
CA2853729A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
CN106632303A (zh) * 2017-01-09 2017-05-10 湖南华腾制药有限公司 一种6‑噻唑基吲哚衍生物的制备方法
TW201925194A (zh) 2017-11-20 2019-07-01 美商雅里俊公司 吲哚化合物及其用途
CN108659003B (zh) * 2018-04-14 2021-01-26 上海朝晖药业有限公司 一种治疗口腔溃疡的化合物的制备方法
TW202039443A (zh) * 2019-01-04 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 ６－側氧基－１，６－二氫噠嗪類衍生物、其製備方法及其在醫藥上的應用
WO2020169042A1 (zh) * 2019-02-20 2020-08-27 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
AU2020258394A1 (en) 2019-04-15 2021-10-28 Ariagen, Inc. Chiral indole compounds and their use
WO2024102758A2 (en) * 2022-11-08 2024-05-16 The General Hospital Corporation N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
HUP0201215A2 (en) 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
KR20030029997A (ko) 2000-09-15 2003-04-16 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
CZ305838B6 (cs) * 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
US20030149038A1 (en) 2001-11-09 2003-08-07 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
CN1596114A (zh) 2001-11-13 2005-03-16 三维药物公司 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用
ATE389400T1 (de) 2001-12-18 2008-04-15 Hoffmann La Roche Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
SG155941A1 (en) * 2004-09-22 2009-10-29 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
DE602007007065D1 (de) 2006-03-22 2010-07-22 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
PA8792401A1 (es) * 2007-08-06 2009-03-31 Janssen Pharmaceutica Nv Fenilendiaminas
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
ES2382701T3 (es) 2007-09-21 2012-06-12 Janssen Pharmaceutica, N.V. Inhibidores de la interacción entre MDM2 y p53

Also Published As

Publication number Publication date
CN102307868B (zh) 2016-06-22
CN102307868A (zh) 2012-01-04
WO2010089327A3 (en) 2010-10-21
EA021883B1 (ru) 2015-09-30
BRPI1008855A2 (pt) 2016-03-15
TWI476189B (zh) 2015-03-11
US8541442B2 (en) 2013-09-24
AU2010210178A1 (en) 2011-07-28
MX2011008195A (es) 2011-09-06
EP2393801B1 (de) 2017-07-12
JP5612611B2 (ja) 2014-10-22
CL2011001860A1 (es) 2012-07-20
US20110294846A1 (en) 2011-12-01
KR20110116195A (ko) 2011-10-25
NO20111199A1 (no) 2011-11-04
BRPI1008855B8 (pt) 2021-05-25
CA2749209A1 (en) 2010-08-12
WO2010089327A2 (en) 2010-08-12
IL214427A0 (en) 2011-09-27
EA201170997A1 (ru) 2012-01-30
UA107455C2 (uk) 2015-01-12
EP2393801A2 (de) 2011-12-14
SG173495A1 (en) 2011-09-29
BRPI1008855B1 (pt) 2020-05-12
CA2749209C (en) 2017-01-10
CO6341625A2 (es) 2011-11-21
AR075235A1 (es) 2011-03-16
JP2012516872A (ja) 2012-07-26
KR101730407B1 (ko) 2017-04-26
ZA201105695B (en) 2014-01-29
MY152018A (en) 2014-08-15
NZ594186A (en) 2012-12-21
AU2010210178B2 (en) 2014-06-05
TW201038552A (en) 2010-11-01
ES2639752T3 (es) 2017-10-30

Similar Documents

Publication Publication Date Title
ZA201105695B (en) Indole derivatives as anticancer agents
IL219087A0 (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
GB0905328D0 (en) Indole derivatives
ZA201104659B (en) Benzothiazole derivatives as anticancer agents
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
ZA201109370B (en) Pyrazinooxazepine derivatives
GB0909441D0 (en) Novel indole derivatives
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
IL212375A0 (en) Naphthamides as anticancer agents
IL225393A0 (en) History of Indole
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed